Key result
AL amyloidosis linked to ~8.7-fold higher mortality in smoldering multiple myeloma.
Why the study?
The clinical characteristics and prognosis of symptomatic and smoldering multiple myeloma with AL amyloidosis are not clearly defined.
Cohort (n=158)
No
Hazard Ratio: 8.741 (95% CI 2.254–33.896)
p-value: p=0.002
AL amyloidosis signals markedly worse survival in smoldering multiple myeloma; leaves open whether screening or intervention alters outcomes in this population.
Background: Amyloid light-chain amyloidosis (AL amyloidosis) is commonly associated with multiple myeloma. However, the clinical characteristics and prognosis of symptomatic and smoldering multiple myeloma with AL amyloidosis are not particularly clear. Methods: Patients with symptomatic and smoldering multiple myeloma in the Peking University First Hospital registry from 2010 to 2018 were studied. The clinical and laboratory information was collected from first presentation to death or until the last available clinical follow-up. The patients’ survival and outcomes were analyzed, and the relationship between the clinical parameters and survival was also assessed. Results: Compared with symptomatic multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP≧700pg/mL ( P < 0.001), ALP> 187.5IU/L ( P =0.032) and ALB< 25g/L ( P < 0.001). Similarly, compared with smoldering multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP≧700pg/mL ( P =0.030) and Alb< 25g/L ( P =0.024). The existence of AL amyloidosis, especially those with the heart involvement, was related to shorter long-term survival of symptomatic and smoldering multiple myeloma according to univariate analyses. Renal involvement and gastrointestinal tract involvement had an impact on the prognosis of smoldering multiple myeloma but not on the symptomatic multiple myeloma. Cox regression model for overall survival detected BNP≧700pg/mL in symptomatic multiple myeloma having independent poorer prognostic significance (HR=2.455, P =0.004). Interestingly, BNP at diagnosis was significantly correlated with cardiac amyloidosis (r=0.496, P < 0.001). Cox regression model for overall survival detected the presence of AL amyloidosis in smoldering multiple myeloma having independent poorer prognostic significance (HR=8.741, P =0.002). Conclusion: AL amyloidosis is an independent poor prognostic factor for not only symptomatic multiple myeloma but also smoldering multiple myeloma. It is mainly because of involvement of important organs, especially the heart. AL amyloidosis probably has a greater impact on the prognosis of smoldering multiple myeloma than on the symptomatic multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) conducted a cohort in Multiple Myeloma (n=158). AL amyloidosis vs. Without AL amyloidosis was evaluated on Overall survival in smoldering multiple myeloma (HR 8.741, 95% CI 2.254-33.896, p=0.002). The presence of AL amyloidosis was an independent poor prognostic factor for overall survival in patients with smoldering multiple myeloma (HR 8.741).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: